![JCM | Free Full-Text | Prostate Cancer Screening with PSA: Ten Years' Experience of Population Based Early Prostate Cancer Detection Programme in Lithuania JCM | Free Full-Text | Prostate Cancer Screening with PSA: Ten Years' Experience of Population Based Early Prostate Cancer Detection Programme in Lithuania](https://www.mdpi.com/jcm/jcm-09-03826/article_deploy/html/images/jcm-09-03826-g001.png)
JCM | Free Full-Text | Prostate Cancer Screening with PSA: Ten Years' Experience of Population Based Early Prostate Cancer Detection Programme in Lithuania
![Prostate specific antigen (PSA) as a long-term marker of risk for prostate cancer | THE "NEW" PROSTATE CANCER INFOLINK Prostate specific antigen (PSA) as a long-term marker of risk for prostate cancer | THE "NEW" PROSTATE CANCER INFOLINK](https://talkaboutprostatecancer.files.wordpress.com/2008/04/newest-lilja-table.png)
Prostate specific antigen (PSA) as a long-term marker of risk for prostate cancer | THE "NEW" PROSTATE CANCER INFOLINK
![Prostate-Specific Antigen Testing: Overview, Physiologic Characteristics of PSA, Other Prostate Cancer Markers Prostate-Specific Antigen Testing: Overview, Physiologic Characteristics of PSA, Other Prostate Cancer Markers](https://img.medscapestatic.com/pi/meds/ckb/07/23507tn.jpg)
Prostate-Specific Antigen Testing: Overview, Physiologic Characteristics of PSA, Other Prostate Cancer Markers
![Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial - The Lancet Oncology Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/100cce14-2b7a-460b-94d7-bd94a42e1f57/gr1.gif)
Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial - The Lancet Oncology
![PSA-Wert: Warum es sich lohnt, ihn zu kennen - Erkrankungen & Therapie - derStandard.at › Gesundheit PSA-Wert: Warum es sich lohnt, ihn zu kennen - Erkrankungen & Therapie - derStandard.at › Gesundheit](https://i.ds.at/qOCboQ/rs:fill:750:0/plain/2017/10/09/prostata.jpg)